← board
MTEX
distress 0/10 · well-funded / low risk$4.38-4%today-57% from 52w high
Revenue
$25M
Liquidity
$7M
Runway
9.3 yrs
Shares 1y
+2%
Price & events
-42.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-4.4%
1D
-7.0%
1W
-18.9%
1M
-6.8%
3M
-42.1%
6M
-47.4%
1Y
-37.4%
2Y
-83.1%
5Y
-73.4%
All
Overview
- Market Cap
- $8.45M
- Enterprise Value
- $4.19M
- Volume
- 17.80K
- 52 Week Range
- $3.95 – $10.19
- Total Shares
- 1.93M
- Float Shares
- 937.92K
- Short %
- 1.07%
- % Held by Insiders
- 56.21%
- % Held by Institutions
- 16.87%
- RVOL
- 1.35x
- Beta
- 0.71
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-04-01enrollment delayNotification of late filing of Form 10-K due to going concern assessmentSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.